Gluscan (Fludeoxyglucose (18f))

Gluscan is a radiopharmaceutical containing the active ingredient fluorodeoxyglucose F‑18 (Fludeoxyglucose (18F)) supplied as an injectable solution for intravenous administration. It is classified as a diagnostic imaging agent used in positron emission tomography (PET) scans. Gluscan is marketed in the European Union and is available by prescription only. The compound acts as a glucose analog that accumulates in metabolically active tissues, enabling visualization of physiological processes.

Gluscan is employed in PET imaging to assess metabolic activity in various organ systems.

- Oncology PET imaging for detection, staging, and treatment monitoring of solid tumors and lymphomas. - Cardiac PET imaging to evaluate myocardial viability and perfusion under stress and rest conditions. - Neurologic PET imaging for assessment of brain glucose metabolism in epilepsy, dementia, and movement disorders. - Research applications investigating pharmacokinetics, inflammation, and infection models.

Adverse reactions to Gluscan are generally mild and related to the injection procedure or transient physiological changes.

Common: - Mild injection site discomfort or erythema lasting a few minutes. - Transient nausea, vomiting, or abdominal discomfort. - Temporary headache or dizziness. - Short‑lasting flushing or warmth sensation.

Serious: - Allergic reactions ranging from urticaria to anaphylaxis. - Significant changes in blood glucose levels in diabetic patients. - Rare radiation‑induced tissue injury at high cumulative doses.

Because Gluscan contains a radioactive tracer, specific precautions are recommended to ensure patient safety and optimal image quality.

- Verify patient fasting status (typically 4–6 hours) to reduce physiologic glucose competition. - Assess renal function; impaired clearance may increase radiation exposure. - Screen for pregnancy and lactation; avoid use unless benefits outweigh potential fetal radiation risk. - Review recent administration of other radiopharmaceuticals to prevent overlapping radiation doses. - Monitor diabetic patients closely, as glucose metabolism may affect tracer distribution. - Ensure proper intravenous line placement to avoid extravasation of the radiotracer.

Gluscan may interact with substances that alter glucose metabolism or affect radiation exposure.

Avoid: - Concurrent use of high‑dose glucose or dextrose solutions immediately before the scan. - Administration of other PET radiotracers within 24 hours, which could confound image interpretation. - Recent exposure to therapeutic radiation therapy that may increase cumulative dose.

Use with caution: - Antidiabetic medications (insulin, oral hypoglycemics) – adjust timing to maintain target glucose levels. - Contrast agents for CT performed in PET/CT studies – consider potential impact on renal function and image quality. - Medications affecting blood flow (vasodilators, beta‑blockers) – may modify tracer distribution.